Genetic Technologies Ltd (GENE) Stock Overview
USA - NASDAQ:GENE - US37185R4065 - ADR
GENE Key Statistics, Chart & Performance
The current stock price of GENE is 0.765 USD. In the past month the price decreased by -3.89%. In the past year, price decreased by -79.19%.
GENE Latest News, Press Relases and Analysis
GENE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.53 | 215.96B | ||
| DHR | DANAHER CORP | 28.89 | 159.49B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.87 | 48.23B | ||
| A | AGILENT TECHNOLOGIES INC | 27.06 | 41.80B | ||
| IQV | IQVIA HOLDINGS INC | 19.17 | 37.38B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.15 | 29.62B | ||
| WAT | WATERS CORP | 29.08 | 21.17B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 44.15 | 22.09B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.72 | 16.76B | ||
| ICLR | ICON PLC | 13.65 | 14.00B | ||
| ILMN | ILLUMINA INC | 24.03 | 15.37B | ||
| TEM | TEMPUS AI INC | N/A | 15.12B |
Related stock screener links
About GENE
Company Profile
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Company Info
Genetic Technologies Ltd
60-66 Hanover St, Fitzroy
Melbourne VICTORIA 3065 AU
CEO: Simon Morriss
Employees: 55
Phone: 61394151135
Genetic Technologies Ltd / GENE FAQ
What is the stock price of Genetic Technologies Ltd today?
The current stock price of GENE is 0.765 USD. The price decreased by -1.92% in the last trading session.
What is the ticker symbol for Genetic Technologies Ltd stock?
The exchange symbol of Genetic Technologies Ltd is GENE and it is listed on the Nasdaq exchange.
On which exchange is GENE stock listed?
GENE stock is listed on the Nasdaq exchange.
What is Genetic Technologies Ltd worth?
Genetic Technologies Ltd (GENE) has a market capitalization of 2.58M USD. This makes GENE a Nano Cap stock.
How many employees does Genetic Technologies Ltd have?
Genetic Technologies Ltd (GENE) currently has 55 employees.
What are the support and resistance levels for Genetic Technologies Ltd (GENE) stock?
Genetic Technologies Ltd (GENE) has a support level at 0.71 and a resistance level at 0.78. Check the full technical report for a detailed analysis of GENE support and resistance levels.
Should I buy Genetic Technologies Ltd (GENE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GENE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GENE, evaluating the profitability, health, valuation and growth aspects
- Genetic Technologies Ltd (GENE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Genetic Technologies Ltd (GENE) Sales and EPS estimates to see what analysts future expectations are.
- Genetic Technologies Ltd (GENE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Genetic Technologies Ltd (GENE) Insider and Institutional Ownership to learn about the owners and their transactions.
- Genetic Technologies Ltd (GENE) Stock Chart to make your own analysis
- Genetic Technologies Ltd (GENE) Latest news and press-releases to stay up to date.
Does Genetic Technologies Ltd (GENE) stock pay dividends?
GENE does not pay a dividend.
What is the Price/Earnings (PE) ratio of Genetic Technologies Ltd (GENE)?
Genetic Technologies Ltd (GENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.74).
GENE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GENE. When comparing the yearly performance of all stocks, GENE is a bad performer in the overall market: 93.77% of all stocks are doing better.
GENE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GENE. Both the profitability and financial health of GENE have multiple concerns.
GENE Financial Highlights
Over the last trailing twelve months GENE reported a non-GAAP Earnings per Share(EPS) of -2.74. The EPS increased by 19.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.25% | ||
| ROE | -656.53% | ||
| Debt/Equity | 0.36 |